Obalon Announces Third Quarter 2020 Financial Results
November 06 2020 - 4:45PM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
medical technology company with the first and only FDA-approved
swallowable, gas-filled intragastric balloon system for the
treatment of obesity, today announced its financial results
for the third quarter ended September 30, 2020.
Financial results for the third quarter of
2020
Revenue for the third quarter of 2020 was $44,000,
compared to $0.3 million for the third quarter of 2019, with the
decrease primarily due to the suspension of operations in the
second quarter of 2020. Net loss for the third quarter of 2020 was
$1.6 million, compared to $3.7 million for the third quarter of
2019. Net loss per share for the third quarter of 2020 was $0.20,
compared to $0.61 for the third quarter of 2019.
Cost of revenue was $41,000 for the third quarter
of 2020, down from $0.4 million for the third quarter of 2019.
Gross profit for the third quarter of 2020 was $3,000 compared to a
gross deficit of $0.1 million for the third quarter of 2019.
Research and Development expense for the third
quarter of 2020 totaled $0.3 million, down from $1.2 million for
the third quarter of 2019. Selling, General and Administrative
expense decreased to $1.3 million for the third quarter of 2020,
compared to $2.5 million for the third quarter of 2019.
Operating loss for the third quarter of 2020 was
$1.6 million, down from a loss of $3.7 million for the third
quarter of 2019.
As of September 30, 2020, the Company had cash and
cash equivalents of $5.5 million and $0.4 million of debt related
to its Payroll Protection Program loan. The Company intends to
continue exploring the potential for third-party reimbursement for
the Obalon Balloon System, as well as exploring and evaluating
financial alternatives to help meet its capital needs and strategic
alternatives that might enhance stockholder value. There is no
assurance that any financial or strategic alternative will be
identified. If the Company is not able to raise additional capital
to meet its needs or to identify a suitable strategic alternative,
it will have to discontinue all operations and may be required to
declare bankruptcy or dissolve.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based
company focused on developing and commercializing novel
technologies for weight loss.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that are not purely historical regarding Obalon’s or its
management’s intentions, beliefs, expectations and strategies for
the future, including those related to new products and their
potential benefits. All forward-looking statements and reasons why
results might differ included in this press release are made as of
the date of this release, based on information currently available
to Obalon, deal with future events, are subject to various risks
and uncertainties, and actual results could differ materially from
those anticipated in those forward looking statements. The risks
and uncertainties that may cause actual results to differ
materially from Obalon’s current expectations are more fully
described in Obalon’s annual report on Form 10-K for the period
ended December 31, 2019, periodic reports on Form 10-Q for the
periods ended September 30, 2020, June 30, 2020 and March 31, 2020
and its other reports, each as filed with the Securities and
Exchange Commission. Except as required by law, Obalon assumes no
obligation to update any such forward-looking statement after the
date of this report or to conform these forward-looking statements
to actual results.
OBALON THERAPEUTICS,
INC.CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE
LOSS(unaudited)(in thousands, except
shares and per share data)
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
$ |
44 |
|
|
$ |
333 |
|
|
$ |
1,527 |
|
|
$ |
2,494 |
|
Cost of revenue |
|
41 |
|
|
|
412 |
|
|
|
1,005 |
|
|
|
2,323 |
|
Gross profit (deficit) |
|
3 |
|
|
|
(79 |
) |
|
|
522 |
|
|
|
171 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
271 |
|
|
|
1,174 |
|
|
|
2,293 |
|
|
|
5,401 |
|
Selling, general and administrative |
|
1,291 |
|
|
|
2,489 |
|
|
|
7,546 |
|
|
|
13,025 |
|
Asset impairment and other charges |
|
— |
|
|
|
— |
|
|
|
1,310 |
|
|
|
— |
|
Total operating expenses |
|
1,562 |
|
|
|
3,663 |
|
|
|
11,149 |
|
|
|
18,426 |
|
Loss from operations |
|
(1,559 |
) |
|
|
(3,742 |
) |
|
|
(10,627 |
) |
|
|
(18,255 |
) |
Interest (expense) income, net |
|
(1 |
) |
|
|
37 |
|
|
|
29 |
|
|
|
(448 |
) |
Other expense, net |
|
— |
|
|
|
(1 |
) |
|
|
(411 |
) |
|
|
(60 |
) |
Net loss and comprehensive loss |
$ |
(1,560 |
) |
|
$ |
(3,706 |
) |
|
$ |
(11,009 |
) |
|
$ |
(18,763 |
) |
Net loss per share, basic and diluted |
$ |
(0.20 |
) |
|
$ |
(0.61 |
) |
|
$ |
(1.42 |
) |
|
$ |
(5.07 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
7,728,639 |
|
|
|
6,061,248 |
|
|
|
7,727,494 |
|
|
|
3,700,538 |
|
OBALON THERAPEUTICS,
INC.CONDENSED CONSOLIDATED BALANCE
SHEETS(in thousands, except shares and par value data)
|
September 30, 2020 |
|
December 31, 2019 |
Assets |
(unaudited) |
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and cash equivalents |
$ |
5,514 |
|
|
$ |
14,055 |
|
Accounts receivable, net |
|
— |
|
|
|
285 |
|
Inventory |
|
— |
|
|
|
1,936 |
|
Other current assets |
|
3,517 |
|
|
|
1,959 |
|
Total current assets |
|
9,031 |
|
|
|
18,235 |
|
Property and equipment, net |
|
982 |
|
|
|
1,081 |
|
Lease right-of-use assets |
|
646 |
|
|
|
1,077 |
|
Other long-term assets |
|
1,303 |
|
|
|
— |
|
Total assets |
$ |
11,962 |
|
|
$ |
20,393 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts payable |
$ |
656 |
|
|
$ |
648 |
|
Accrued compensation |
|
116 |
|
|
|
820 |
|
Deferred revenue |
|
61 |
|
|
|
424 |
|
Other current liabilities |
|
3,634 |
|
|
|
1,524 |
|
Current portion of lease liabilities |
|
583 |
|
|
|
561 |
|
Total current liabilities |
|
5,050 |
|
|
|
3,977 |
|
Lease liabilities, long-term |
|
553 |
|
|
|
567 |
|
Long-term debt |
|
430 |
|
|
|
— |
|
Other long-term liabilities |
|
7 |
|
|
|
— |
|
Total long-term liabilities |
|
990 |
|
|
|
567 |
|
Total liabilities |
|
6,040 |
|
|
|
4,544 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
Common stock, $0.001 par value; 100,000,000 shares authorized as of
September 30, 2020 and December 31, 2019; 7,770,698 and 7,724,100
shares issued and outstanding as of September 30, 2020 and December
31, 2019, respectively |
|
8 |
|
|
|
8 |
|
Additional paid-in capital |
|
189,353 |
|
|
|
188,271 |
|
Accumulated deficit |
|
(183,439 |
) |
|
|
(172,430 |
) |
Total stockholders’ equity |
|
5,922 |
|
|
|
15,849 |
|
Total liabilities and stockholders’ equity |
$ |
11,962 |
|
|
$ |
20,393 |
|
OBALON THERAPEUTICS,
INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS(unaudited)(in thousands)
|
Nine Months Ended September
30, |
|
2020 |
|
2019 |
Operating activities: |
|
|
|
|
|
|
|
Net loss |
$ |
(11,009 |
) |
|
$ |
(18,763 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
Depreciation |
|
260 |
|
|
|
361 |
|
Stock-based compensation |
|
1,021 |
|
|
|
2,300 |
|
Issuance of cash-settled options |
|
7 |
|
|
|
— |
|
Issuance of warrants for the purchase of common stock |
|
45 |
|
|
|
— |
|
Loss on disposal of fixed assets |
|
— |
|
|
|
128 |
|
Amortization of right-of-use assets |
|
378 |
|
|
|
301 |
|
Accretion of investment discount, net |
|
— |
|
|
|
(2 |
) |
Amortization of debt discount |
|
— |
|
|
|
70 |
|
Impairment of long-lived assets and other charges |
|
1,257 |
|
|
|
— |
|
Impairment of inventory |
|
53 |
|
|
|
— |
|
Change in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable, net |
|
285 |
|
|
|
632 |
|
Inventory |
|
(524 |
) |
|
|
(117 |
) |
Other long-term assets |
|
(9 |
) |
|
|
— |
|
Other current assets |
|
(1,389 |
) |
|
|
1,604 |
|
Accounts payable |
|
8 |
|
|
|
(724 |
) |
Accrued compensation |
|
(688 |
) |
|
|
(3,097 |
) |
Deferred revenue |
|
(363 |
) |
|
|
(69 |
) |
Lease liabilities, net |
|
(293 |
) |
|
|
(248 |
) |
Other current and long term liabilities |
|
2,107 |
|
|
|
(363 |
) |
Net cash used in operating activities |
|
(8,854 |
) |
|
|
(17,987 |
) |
Investing activities: |
|
|
|
|
|
|
|
Maturities of short-term investments |
|
— |
|
|
|
2,550 |
|
Purchase of property and equipment |
|
(117 |
) |
|
|
(44 |
) |
Net cash (used in) provided by investing activities |
|
(117 |
) |
|
|
2,506 |
|
Financing activities: |
|
|
|
|
|
|
|
Proceeds from long-term loan |
|
430 |
|
|
|
10,000 |
|
Payment on long-term loan |
|
— |
|
|
|
(20,000 |
) |
Proceeds from issuance of common and warrants, net of paid issuance
costs |
|
— |
|
|
|
15,014 |
|
Proceeds from issuance of common stock, net of issuance costs |
|
— |
|
|
|
8,659 |
|
Proceeds from sale of common stock upon exercise of stock
options |
|
— |
|
|
|
1 |
|
Net cash provided by financing activities |
|
430 |
|
|
|
13,674 |
|
Net decrease in cash and cash equivalents |
|
(8,541 |
) |
|
|
(1,807 |
) |
Cash and cash equivalents at beginning of period |
|
14,055 |
|
|
|
21,187 |
|
Cash and cash equivalents at end of period |
$ |
5,514 |
|
|
$ |
19,380 |
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
Interest paid |
$ |
— |
|
|
$ |
700 |
|
Unpaid issuance costs |
$ |
— |
|
|
$ |
295 |
|
For Obalon Therapeutics, Inc.
Investor Contact:
Andrew Rasdal
President and Chief Executive Officer
Obalon Therapeutics, Inc.
Office: +1 844 362 2566
arasdal@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024